Comparative Pharmacology
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus PMB 200.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE versus PMB 200.
LEVONORGESTREL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE vs PMB 200
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive. Ethinyl estradiol and levonorgestrel inhibit gonadotropin release (FSH, LH), suppressing ovulation. Progestin effect: thickens cervical mucus, alters endometrial receptivity. Ferrous fumarate provides iron supplementation during placebo phase.
PMB 200 is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a calcium channel blocker (CCB). The ARB component blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. The CCB component inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, resulting in peripheral vasodilation and decreased blood pressure.
One tablet (0.15 mg levonorgestrel, 0.03 mg ethinyl estradiol, 75 mg ferrous fumarate) orally once daily at the same time for 21 consecutive days, followed by one ferrous fumarate-only tablet (75 mg) orally once daily for 7 days (28-day cycle).
2.5 mg orally once daily, increased to 5 mg after 2 weeks if tolerated; maximum 10 mg once daily.
None Documented
None Documented
Levonorgestrel: ~25 hours, steady-state after 5 days. Ethinyl estradiol: ~13 hours (7–20). Ferrous fumarate: not applicable.
Terminal elimination half-life 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min), necessitating dose adjustment
Levonorgestrel: ~45% renal, ~32% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Ferrous fumarate: iron excreted in feces as unabsorbed; minimal renal.
Renal (80% unchanged, 15% as glucuronide conjugate), biliary/fecal (5%)
Category D/X
Category C
Estrogen
Estrogen/Progestin Combination